SeaStar Medical CEO to Present at HC Wainwright Conference
Event summary
- SeaStar Medical CEO Eric Schlorff to present at HC Wainwright 28th Annual Global Investment Conference on September 14–16, 2026.
- Presentation available online from September 11, 2026, for 60 days.
- SeaStar Medical's QUELIMMUNE (SCD-PED) is the only FDA-approved treatment for life-threatening AKI in pediatric patients due to sepsis.
- Company's SCD therapy has Breakthrough Device Designation for six indications, accelerating approval pathways.
- NEUTRALIZE-AKI pivotal trial ongoing for adult AKI patients, a condition affecting 200,000+ adults annually in the U.S.
The big picture
SeaStar Medical's participation in the HC Wainwright conference underscores its push to expand investor awareness amid a critical phase of clinical and commercial development. The company's focus on ultra-rare and high-mortality conditions positions it in a niche but high-value segment of the critical care market, where regulatory advantages like Breakthrough Device Designation can translate into competitive differentiation. Success in adult AKI could significantly broaden its addressable market.
What we're watching
- Regulatory Momentum
- Whether SeaStar Medical can leverage its Breakthrough Device Designations to expedite additional approvals and expand its product portfolio.
- Clinical Trial Progress
- The pace at which the NEUTRALIZE-AKI trial delivers results, which could unlock a significant adult patient market.
- Market Penetration
- How SeaStar Medical scales commercial adoption of QUELIMMUNE in the ultra-rare pediatric AKI space.
Related topics